GSA Capital Partners LLP Has $1.05 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Key Points

• GSA Capital Partners LLP increased its stake in BioMarin Pharmaceutical Inc. by 99.7%, now holding 14,811 shares worth approximately $1.05 million.
• Other institutional investors, including Dodge & Cox and Capital Research Global Investors, have also significantly increased their holdings in BioMarin, highlighting strong institutional interest with nearly 99% of stock owned by institutional investors.
• Analysts have issued mixed ratings on BioMarin, with a consensus target price of $93.74 and 19 analysts rating the stock as a buy.

GSA Capital Partners LLP increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 99.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,811 shares of the biotechnology company's stock after buying an additional 7,393 shares during the period. GSA Capital Partners LLP's holdings in BioMarin Pharmaceutical were worth $1,047,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Dodge & Cox grew its stake in BioMarin Pharmaceutical by 6.1% in the fourth quarter. Dodge & Cox now owns 14,746,235 shares of the biotechnology company's stock valued at $969,270,000 after acquiring an additional 847,917 shares during the period. Capital Research Global Investors lifted its holdings in shares of BioMarin Pharmaceutical by 23.8% in the 4th quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company's stock worth $853,944,000 after purchasing an additional 2,496,817 shares in the last quarter. Geode Capital Management LLC grew its position in BioMarin Pharmaceutical by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 3,288,778 shares of the biotechnology company's stock valued at $215,784,000 after purchasing an additional 28,728 shares during the period. Northern Trust Corp increased its stake in BioMarin Pharmaceutical by 16.2% during the 4th quarter. Northern Trust Corp now owns 1,725,039 shares of the biotechnology company's stock valued at $113,387,000 after purchasing an additional 240,681 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in BioMarin Pharmaceutical by 114.5% during the fourth quarter. AQR Capital Management LLC now owns 1,283,599 shares of the biotechnology company's stock worth $84,371,000 after buying an additional 685,099 shares during the last quarter. 98.71% of the stock is owned by institutional investors.

Insider Activity

In related news, CAO Erin Burkhart sold 1,786 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total value of $105,927.66. Following the completion of the transaction, the chief accounting officer directly owned 14,173 shares of the company's stock, valued at approximately $840,600.63. This trade represents a 11.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.85% of the stock is currently owned by company insiders.

BioMarin Pharmaceutical Price Performance

NASDAQ BMRN opened at $57.85 on Friday. The company has a quick ratio of 3.49, a current ratio of 5.52 and a debt-to-equity ratio of 0.10. The company has a market cap of $11.09 billion, a PE ratio of 21.51, a price-to-earnings-growth ratio of 0.81 and a beta of 0.17. BioMarin Pharmaceutical Inc. has a 52 week low of $52.93 and a 52 week high of $94.85. The firm's 50-day simple moving average is $57.09 and its two-hundred day simple moving average is $61.83.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on BMRN shares. The Goldman Sachs Group reduced their price objective on shares of BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating for the company in a report on Monday, May 5th. JPMorgan Chase & Co. lifted their price target on BioMarin Pharmaceutical from $108.00 to $113.00 and gave the company an "overweight" rating in a research note on Monday, July 14th. Morgan Stanley lowered their price objective on BioMarin Pharmaceutical from $97.00 to $96.00 and set an "overweight" rating for the company in a research note on Tuesday, July 22nd. Citigroup cut their target price on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Finally, Wolfe Research set a $95.00 price target on BioMarin Pharmaceutical and gave the stock an "outperform" rating in a report on Tuesday, July 15th. Six research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $93.74.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.